Drug Insights

Effortless Searching: How to Find Nifedipine on Synapse

12 March 2024
2 min read

Nifedipine is a small molecule drug that acts as a blocker of voltage-dependent calcium channels (VDCCs), which are involved in the regulation of calcium ions in the cardiovascular system. By inhibiting these channels, nifedipine reduces calcium influx into smooth muscle cells, leading to vasodilation and a decrease in blood pressure. This drug is primarily used to treat hypertension, including renovascular and essential hypertension, as well as angina pectoris and other cardiovascular diseases. Nifedipine was first developed and marketed by Bayer AG, and received its first approval in 1975. Since then, it has become a widely used medication for the management of hypertension and related conditions, although its use is associated with potential adverse effects such as hypotension, dizziness, and headache. As such, it should be used with caution and under the supervision of a healthcare professional. Click on the image below to begin the exploration journey of Nifedipine through the Synapse database!

图形用户界面, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Akari Therapeutics Merges with Peak Bio to Expand ADC Portfolio
Latest Hotspot
3 min read
Akari Therapeutics Merges with Peak Bio to Expand ADC Portfolio
7 March 2024
Akari Therapeutics and Peak Bio have reached a final merger agreement, positioning themselves as partners to develop a broader portfolio with an innovative Antibody Drug Conjugate (ADC) technology base.
Read →
Advancements in Clinical Research and Development of Obesity Treatment Medications
Hot Spotlight
21 min read
Advancements in Clinical Research and Development of Obesity Treatment Medications
7 March 2024
In February, University of Leicester and Leicester Diabetes Centre experts published a summary of obesity treatments in "International Journal of Obesity," highlighting new drugs inspired by gut incretin hormones.
Read →
1.0 mg Semaglutide Reduces Kidney Disease Events by 24% in Type 2 Diabetics with Chronic Conditions
Latest Hotspot
3 min read
1.0 mg Semaglutide Reduces Kidney Disease Events by 24% in Type 2 Diabetics with Chronic Conditions
7 March 2024
Administering 1.0 mg of Semaglutide led to a 24% decrease in occurrences related to kidney disease among individuals with type 2 diabetes and persistent kidney conditions.
Read →
Making the Most Out of Synapse: Searching for Codeine
Drug Insights
2 min read
Making the Most Out of Synapse: Searching for Codeine
7 March 2024
Codeine, a diminutive molecular compound, exerts its agonistic influence upon opioid receptors situated within the central nervous system.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.